Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/112180
DC FieldValueLanguage
dc.contributor.authorGutiérrez Cabrera, Carlos Javieren_US
dc.contributor.authorGonzález Martín, Margarita Rosaen_US
dc.contributor.authorCorbera Sánchez, Juan Albertoen_US
dc.contributor.authorTejedor Junco, María Teresaen_US
dc.date.accessioned2021-10-08T11:28:52Z-
dc.date.available2021-10-08T11:28:52Z-
dc.date.issued2013en_US
dc.identifier.isbn978-84-942134-1-0en_US
dc.identifier.urihttp://hdl.handle.net/10553/112180-
dc.description.abstractTrypanosomoses are protozoan diseases, affecting both human and animals, and mainly found in tropical Africa, Latin America and Asia. In Africa, trypanosomes produce serious diseases in human beings such as West and East Sleeping Sickness caused by T. brucei gambiense and T. brucei congolense respectively, while in the Americas T. cruzi causes the Chagas disease. Other species of Trypanosoma affect animals and produce enormous economical impact in the endemic areas. Those species could be classified as those transmitted by tsetse flies- (Trypanosoma vivax, T. congolense and T. brucei brucei) producing a disease known as nagana and those non-transmitted by tsetse- (T. evansi –surra-, T. equiperdum–dourine-). Due to antigenic variation shown by the trypanosome, prophylaxis of these diseases using vaccines is challenging; for that, most of the control and eradication programs against animal trypanosomes carried out in the infected areas in the world are based on therapeutic and prophylactic measures, using trypanocidal drugs or combining both measures. However, only three compounds are available in the market (isometamidium chloride, homidium –bromide and chloride- and diminazene aceturate) and all of them have been on the market for over 40 years. One of the most important risks for the future use of these existing trypanocides is the development and dissemination of resistances and, for that, new drugs have been developed in the recent past and are available in the market to treat T. evansi (melarsomine) and, on the other hand, new anti-trypanosomes candidates are being developed and tested at clinical trial level presently. The aim of the present chapter is to review the current status of the therapeutic and prophylactic agents used for the control of pathogenic animal trypanosomes as well as the potential candidates that are tested nowadays as possible new trypanocides to be used in the next future.en_US
dc.languageengen_US
dc.publisherFormatex Research Center S.L.en_US
dc.relationNuevas diamidinas como candidatos clínicos contra la tripanosomosis animal por T. evansi. Estudio basado en un modelo caprino (SolSubC200801000100)en_US
dc.sourceMicrobial pathogens and strategies for combating them: science, technology and education, p. 1564-1573en_US
dc.subject310907 Patologíaen_US
dc.subject320505 Enfermedades infecciosasen_US
dc.subject.otherAnimal trypanosomosisen_US
dc.subject.otherTrypanosoma evansien_US
dc.subject.otherBruceien_US
dc.subject.otherVivaxen_US
dc.subject.otherCongolenseen_US
dc.subject.otherEquiperdumen_US
dc.subject.otherTrypanocidesen_US
dc.titleChemotherapeutic agents against pathogenic animal trypanosomesen_US
dc.typeinfo:eu-repo/semantics/bookParten_US
dc.typeBookParten_US
dc.investigacionCiencias de la Saluden_US
dc.type2Capítulo de libroen_US
dc.utils.revisionen_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-VETen_US
dc.contributor.buulpgcBU-VETen_US
dc.contributor.buulpgcBU-VETen_US
dc.contributor.buulpgcBU-VETen_US
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptGIR IUIBS: Medicina Veterinaria e Investigación Terapéutica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptGIR IUIBS: Trypanosomosis, Resistencia a Antibióticos y Medicina Animal-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.deptGIR IUIBS: Trypanosomosis, Resistencia a Antibióticos y Medicina Animal-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Patología Animal, Producción Animal, Bromatología y Tecnología de Los Alimentos-
crisitem.author.deptGIR IUIBS: Trypanosomosis, Resistencia a Antibióticos y Medicina Animal-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.orcid0000-0003-0764-7408-
crisitem.author.orcid0000-0002-4457-2321-
crisitem.author.orcid0000-0001-7812-2065-
crisitem.author.orcid0000-0003-2387-1426-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameGutiérrez Cabrera,Carlos Javier-
crisitem.author.fullNameGonzález Martín, Margarita Rosa-
crisitem.author.fullNameCorbera Sánchez, Juan Alberto-
crisitem.author.fullNameTejedor Junco, María Teresa-
Appears in Collections:Capítulo de libro
Show simple item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.